Search
Immunitybio Inc
IBRXAdd to Watchlist
8.870USD
+0.420+4.97%
Market hours 09/22, 11:53（ET）
9.34BMarket Cap
LossP/E TTM
Immunitybio Inc (IBRX) Stock Price Target & Forecast
Analyst Rating
Based on 4 analysts giving stock ratings to Immunitybio Inc in the past month.
Strong Buy
2 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
12.750USD+50.35%
IBRX Analyst Recommendation Trends
In the current month, IBRX has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IBRX average Analyst price target in the last month is 12.750.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
4
4
5
5
5
5
IBRX Analyst Rating for Peer Comparison
Updated: Sep 21, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
7
7
1
1
21
Financial Forecasting
Based on analysts' estimates, IBRX EPS is projected to reach -0.067 in FY2026Q3, following reported EPS of -0.219 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.09
-0.07
-0.09
-0.07
-0.06
Actual
-0.06
-0.62
-0.22
--
--
Surprise
+33.47%
-780.31%
-143.77%
--
--
FAQs
What is Immunitybio Inc's expected revenue for the next quarter?
Immunitybio Inc's expected revenue is 59.25M.
What is Immunitybio Inc's price target?
Analysts forecast that Immunitybio Inc's price target is USD 12.75, with the highest forecast at USD 15.00 and the lowest forecast at USD 12.00.
How have Immunitybio IncIBRX's recent earnings per share performed?
The market expectation was USD -0.22, while Immunitybio IncIBRX's earnings per share (EPS) for the previous quarter was USD -0.62. EPS for the next quarter is expected at USD -0.07.
What is the analyst rating for Immunitybio Inc?
Based on the ratings of Immunitybio Inc's stock from 4 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.